利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.031 秒)

    Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
    1.
    发明申请
    Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists 审中-公开
    用腺苷A3受体激动剂增强HIF-1介导的病症的治疗

    公开(公告)号：US20060194756A1

    公开(公告)日：2006-08-31

    申请号：US11286129

    申请日：2005-11-22

    申请人： Pier Borea ,  Pier Baraldi ,  Stefania Merighi ,  Stephen MacLennan ,  Edward Leung ,  Allan Moorman

    发明人： Pier Borea ,  Pier Baraldi ,  Stefania Merighi ,  Stephen MacLennan ,  Edward Leung ,  Allan Moorman

    IPC分类号： A61K31/7076

    CPC分类号： A61K31/7076 ,  A61K31/519 ,  C07D487/04 ,  C07D487/14 ,  C07K16/18

    摘要： The present invention relates to the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with under-expression of HIF-1α and/or decreased HIF-1 α activity (e.g., ischemic related disorders). The methods of the invention are directed to methods of reducing tissue damage (e.g., substantially prevention tissue damage, inducing tissue protection) resulting from ischemia orhypoxia. The invention provides methods for treating, preventing and/or ameliorating one or more symptoms of hypoxic or HIF-1α related disorders by administering an A3 receptor agonist either alone or in combination with other agents.

    摘要翻译： 本发明涉及腺苷受体激动剂，优选A 3 N 3受体激动剂，单独使用或与其它药剂组合用于治疗，预防和/或控制与低血糖相关的疾病或病症， HIF-1α的表达和/或降低的HIF-1α活性（例如缺血性相关疾病）。 本发明的方法涉及减少由局部缺血或缺氧引起的组织损伤（例如，基本上预防组织损伤，诱导组织保护）的方法。 本发明提供了通过单独或与其它药剂组合施用A 3 O 3受体激动剂来治疗，预防和/或改善一种或多种缺氧或HIF-1α相关疾病症状的方法。

    Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
    2.
    发明申请
    Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists 审中-公开
    用腺苷A3受体拮抗剂增强癌症和HIF-1介导的病症的治疗

    公开(公告)号：US20060204502A1

    公开(公告)日：2006-09-14

    申请号：US11286127

    申请日：2005-11-22

    申请人： Pier Borea ,  Pier Baraldi ,  Stefania Merighi ,  Stephen MacLennan ,  Edward Leung ,  Allan Moorman

    发明人： Pier Borea ,  Pier Baraldi ,  Stefania Merighi ,  Stephen MacLennan ,  Edward Leung ,  Allan Moorman

    IPC分类号： A61K39/395 ,  A61K31/519

    CPC分类号： A61K31/7076 ,  A61K31/519 ,  C07D487/04 ,  C07D487/14 ,  C07K16/18

    摘要： The present invention relates to the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with overexpression of HIF-1α and/or increased HIF-1α activity (e.g., cancer, respiratory disease). The methods and compositions of the invention are particularly useful for preventing, treating, or ameliorating symptoms associated with a cancer, disease or disorder associated with hypoxia-inducible factor 1α (HIF-1α) using the A3 receptor antagonists of the invention. The present invention provides methods to inhibit the growth of tumors, particularly solid tumors and more particularly hypoxic tumors.

    摘要翻译： 本发明涉及腺苷受体拮抗剂，优选Aβ3受体拮抗剂，其单独使用或与其它药物组合用于治疗，预防和/或控制与过表达相关的疾病或病症 HIF-1α和/或增加的HIF-1α活性（如癌症，呼吸系统疾病）。 本发明的方法和组合物特别可用于预防，治疗或改善与使用Aβ受体相关的与缺氧诱导因子1α（HIF-1α）相关的癌症，疾病或病症相关症状。 本发明的拮抗剂。 本发明提供抑制肿瘤，特别是实体瘤，特别是缺氧性肿瘤生长的方法。

    Use of adenosine A3 receptor antagonists to inhibit tumor growth
    5.
    发明授权
    Use of adenosine A3 receptor antagonists to inhibit tumor growth 失效
    使用腺苷A3受体拮抗剂抑制肿瘤生长

    公开(公告)号：US06326390B1

    公开(公告)日：2001-12-04

    申请号：US09377271

    申请日：1999-08-19

    申请人： Edward Leung ,  Pier Giovanni Baraldi ,  Pier Andrea Borea ,  Shih-Fong Chen

    发明人： Edward Leung ,  Pier Giovanni Baraldi ,  Pier Andrea Borea ,  Shih-Fong Chen

    IPC分类号： A61K3141

    CPC分类号： A61K31/7076 ,  A61K31/00 ,  A61K31/519 ,  A61K45/06

    摘要： Tumor growth and metastasis can be inhibited by administration of adenosine A1 and/or A3 antagonists, preferably A3 antagonists, to a patient. The antagonists can be, and preferably are, administered in combination with other anti-tumor agents, such as anti-angiogenic agents (including adenosine A2a antagonists) and/or cytotoxic agents. Because the cytotoxic agents attack the tumor cells themselves, and the anti-angiogenic agents prevent the growth of vasculature which would otherwise support the growth of the tumor cells.

    摘要翻译： 通过向患者施用腺苷A1和/或A3拮抗剂，优选A3拮抗剂，可以抑制肿瘤生长和转移。 拮抗剂可以并且优选与其它抗肿瘤剂如抗血管生成剂（包括腺苷A2a拮抗剂）和/或细胞毒性剂组合施用。 因为细胞毒性剂本身攻击肿瘤细胞，并且抗血管生成剂阻止脉管系统的生长，否则其将支持肿瘤细胞的生长。

    Method for treating hyper-excited sensory nerve functions in humans
    6.
    发明授权
    Method for treating hyper-excited sensory nerve functions in humans 有权
    治疗人体超兴奋感觉神经功能的方法

    公开(公告)号：US06248774B1

    公开(公告)日：2001-06-19

    申请号：US09654994

    申请日：2000-09-05

    申请人： Edward Leung

    发明人： Edward Leung

    IPC分类号： A61K3138

    CPC分类号： A61K31/38

    摘要： A method of and a formulation for treating hyper-excited sensory nerve functions are provided. The method comprises administering to a patient in need of treatment thereof a pharmaceutical composition comprising an effective amount of 2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof. The disorder treated include hyperesthesia, dysesthesia, allodynia, hyperalgesia, tinnitus, ganglionic dysfunction and combinations thereof. The co-administration of adenosine is not needed. The pharmaceutical preparation is suitable for oral administration. The pharmaceutical preparation is useful in the reduction of neuropathic pain in a conscious human. The use of the pharmaceutical preparation does not result in medically adverse cardiovascular symptoms associated with administration of adenosine.

    摘要翻译： 提供了一种治疗超兴奋性感觉神经功能的方法和制剂。 该方法包括向需要治疗的患者施用包含有效量的2-氨基-4,5,6,7-四氢苯并[b]噻吩-3-基）（4-氯苯基）甲酮或 其药学上可接受的盐。 所治疗的疾病包括感觉异常，感觉障碍，异常性疼痛，痛觉过敏，耳鸣，神经节功能障碍及其组合。 不需要腺苷的共同给药。 该药物制剂适合于口服给药。 药物制剂可用于减少有意识的人的神经性疼痛。 药物制剂的使用不会导致与给予腺苷相关的医学上不利的心血管症状。

    METHODS OF TREATING ATHEROSCLEROSIS
    10.
    发明申请
    METHODS OF TREATING ATHEROSCLEROSIS 审中-公开
    治疗甲状腺功能亢进症的方法

    公开(公告)号：US20110190324A1

    公开(公告)日：2011-08-04

    申请号：US12997963

    申请日：2009-07-15

    申请人： Edward Leung

    发明人： Edward Leung

    IPC分类号： A61K31/519 ,  A61P9/10

    CPC分类号： A61K31/522 ,  A61K31/519

    摘要： The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A3 receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.

    摘要翻译： 本发明涉及腺苷A3受体拮抗剂及其用于预防和治疗动脉粥样硬化的用途，其通过向有需要的哺乳动物施用治疗有效量的腺苷A3受体拮抗剂或其药学上可接受的盐，单独使用或在 与其他抗动脉粥样硬化剂组合。